




The relative strengths and weaknesses of Immune Design CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Immune Design CORP compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 137% points. The greatest weakness of Immune Design CORP is the variable Research and Development, reducing the Economic Capital Ratio by 12% points.

The company's Economic Capital Ratio, given in the ranking table, is 383%, being 120% points above the market average of 263%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	115,560	Assets	116,145
Cost of Goods Sold	0	Liabilities	7,111
Intangible Assets	0	Expenses	48,995
Liabilities, Current	7,111	Revenues	9,510
Liabilities, Non-Current	0	Stockholders Equity	109,034
Other Assets	0	Net Income	-39,485
Other Compr. Net Income	0	Comprehensive Net Income	-39,485
Other Expenses	774	BaseVar	90,880
Other Liabilities	0	ECR before LimitedLiability	322%
Other Net Income	0	Economic Capital Ratio	383%
Other Revenues	9,510		
Property and Equipment	585		
Research and Development	33,087		
Selling, General and Administrative Expense	15,134		